Wragge Lawrence Graham & Co's intellectual property (IP) experts in Munich have worked with Ashurst LLP to advise Novacap Group on its acquisition of pharmaceutical company CU Chemie Uetikon (Uetikon) for an undisclosed sum.

Ashurst instructed Dr Ina Gerstberger of Wragge Lawrence Graham & Co's Munich office on the basis of her specialist knowledge relating to transactional and regulatory pharmaceutical and chemical law.

Ina worked with Ashurst's team to advise Novacap on its acquisition of specialist chemical and pharmaceutical manufacturer Uetikon. Ina and associate Stefanie Fuchs were involved in the due diligence work relating to regulatory law for pharmaceuticals and chemicals, and on commercial contracts.

Ina was also tasked with investigating European Union regulations and compliance concerning the Registration, Evaluation, Authorisation and restriction of Chemicals (REACH).

Ina said: "This was an interesting deal to work on, involving working on the acquisition but also compliance research into the REACH regulation. It's a great acquisition for Novacap - in 2014 Uetikon had a turnover of around €40 million."

Funds advised by finance investor Equistone Partners Europe sold the shares in Uetikon.

Novacap is a leading manufacturer and distributor of essential chemicals for use in everyday products. It is the world leader in the production and distribution of aspirin, paracetamol, sodium bicarbonate and other household names.

Wragge Lawrence Graham & Co advises on the full range of IP issues from offices in the UK, Germany, France and China. Acting for some of the world's biggest organisations, its clients range from global pharmaceutical companies and leading research and academic bodies, to small private companies and start-up businesses.